Resources

AddToAny

Google+ Facebook Twitter Twitter

Tech news: October 2020

This month's top tech news stories

Arginase 2

Researchers at the Cancer Research UK-AstraZeneca Antibody Alliance Laboratory in Cambridge, UK have pioneered the development of an innovative affinity maturation technique to generate an inhibitory, high-affinity antibody against Arginase 2 (ARG2) – an enzyme implicated in major human diseases including cancer.

ARG2 targets and destroys L-arginine, an amino acid critical for immune cells to fight diseases such as cancer, as well as infections.

cancerresearchuk.org


SARS-CoV-2 test

Avacta Group is launching an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus.

Enzyme linked immunosorbent assays (“ELISAs”) are research tools used to detect and quantify a target of interest in a wide range of samples. Using the same Affimer reagents that are incorporated into its rapid coronavirus saliva test, Avacta has developed an ELISA laboratory test to detect SARS-CoV-2.  

avacta.com


Digital pathology

Philips has supported Oxford University Hospitals (OUH) NHS Foundation Trust to become one of the earliest UK adopters of a fully digitised cellular pathology (histopathology) department.

OUH is one of the first NHS trusts in the country to achieve the status of digitising all surgical histology and referral slides within the cellular pathology department.

This step-change is expected to unlock greater collaboration between OUH and its wider network of trusts and pathologists.  

philips.co.uk

Download PDF


Picture Credit | Digital Pathology

Related Articles

All-in-one Covid surveillance test

A new type of COVID-19 testing strategy could help streamline the process of identifying cases, tracking variants and detecting co-infecting viruses, it is claimed.

Ultra-sensitive rapid diagnostic for Ebola

An interdisciplinary team of scientists has developed a highly sensitive and rapid diagnostic test for Ebola virus (EBOV) infection.

Novel Covid test

A new rapid test has been developed that is 98.3% accurate for positive COVID-19 tests and 96% for negative tests.

Top